Recently, the 1st Bohai Rim Urology Academic Conference and the 6th Haihe Symposium on Reproductive and Sexual Medicine drew to a successful close in Tianjin. Jointly hosted by the Tianjin Association of Integrative Chinese and Western Medicine, the Beijing Health Promotion Association and the Beijing Zhongjianlian Health Service Promotion Center, the conference convened leading experts and scholars in urology, reproductive medicine and sexual medicine across the Bohai Rim region, conducting in-depth discussions on cutting-edge diagnostic and therapeutic technologies, clinical applications and academic research in andrology and urology.
Distinguished Experts Convene to Inaugurate an Academic Forum
At the opening ceremony, Professor Niu Yuanjie of Tianjin Medical University General Hospital and Professor Xin Zhongcheng of the Second Hospital of Tianjin Medical University successively delivered opening addresses. They extended their congratulations on the convening of the conference and expressed their expectation that the meeting would establish a high-calibre academic exchange platform, promote the coordinated development of urology and reproductive–sexual medicine across the Bohai Rim region, accelerate the clinical translation of novel technologies and therapies, and ultimately benefit a broader patient population.
Advances in Micro-Energy Medicine: Iteration and Clinical Value
Professor Xin Zhongcheng
The Second Hospital of Tianjin Medical University
Professor Xin Zhongcheng of the Second Hospital of Tianjin Medical University delivered a featured lecture at the plenary session. Focusing on the progress of micro-energy medicine in clinical application, he delivered an in-depth exposition on the technological merits and clinical value of domestically developed WBL Low-Intensity Pulsed Ultrasound (LIPUS), offering an innovative non-invasive diagnostic and therapeutic paradigm for refractory andrological pelvic-floor disorders such as chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS).
Professor Xin systematically reviewed the developmental trajectory of micro-energy technologies in andrology, noting that domestic non-invasive andrological diagnosis and treatment had long been constrained by imported technologies with limited clinical applicability. In 2014, WBL's independently developed LIPUS achieved a core technological breakthrough and was formally introduced into andrological clinical practice, breaking the foreign technological monopoly and ushering in a domestically driven innovation in micro-energy andrological care.
Multiple authoritative clinical studies have confirmed that WBL LIPUS is safe, reliable and demonstrably efficacious in the treatment of erectile dysfunction (ED). The technology precisely targets lesion tissue and effectively promotes the regeneration and repair of local vasculature and nerves. By virtue of its high safety profile, broad indications and repeatable non-invasive delivery, it compensates for the many shortcomings of conventional diagnostic and therapeutic modalities.
As clinical research continues to deepen, WBL LIPUS has expanded from ED into the more refractory CP/CPPS domain. Addressing the clinical pain point of recurrent, hard-to-eradicate CP/CPPS symptoms, Professor Xin highlighted the standardised application essentials of LIPUS, noting that its core attributes—non-invasiveness, safety, precision, absence of side-effects and suitability for long-term intervention—overcome the shortcomings of traditional therapies. It thus provides a novel, high-quality non-pharmacological option for andrological pelvic-floor chronic disorders and stands as a mainstream micro-energy modality in contemporary andrological practice.
WBL LIPUS Accelerates the Clinical Translation and Adoption of Domestic Technology
As the first enterprise in China's medical-device industry to be featured on CCTV's "Sci-Tech China" programme, WBL Medical Group has long been committed to the core track of micro-energy medicine, continuously focusing on the independent R&D, technological iteration and clinical translation of LIPUS low-intensity pulsed ultrasound. It is the earliest innovation-driven enterprise in China dedicated to non-invasive LIPUS-based andrological diagnosis and treatment.
Compared with industry-standard technologies, WBL LIPUS draws on the Group's solid scientific research foundation, comprehensive technological system and extensive clinical data to specifically tackle the diagnostic and therapeutic pain points of andrological pelvic-floor chronic disorders. WBL continues to advance the clinical application of LIPUS in highly prevalent andrological conditions such as erectile dysfunction (ED) and chronic pelvic pain syndrome (CP/CPPS), iteratively refining its technical parameters and standardising diagnostic and therapeutic protocols, thereby driving China's domestic micro-energy ultrasound technology from fundamental research to standardised, large-scale clinical deployment.
Extracorporeal Pulsed-Ultrasound Pelvic-Floor Therapeutic Platform
The Group's WBL LIPUS Extracorporeal Pulsed-Ultrasound Pelvic-Floor Therapeutic Platform is China's first dedicated extracorporeal ultrasound device for chronic inflammation and chronic pelvic pain syndrome (CP/CPPS). The platform delivers extracorporeal pulsed ultrasound that penetrates the pelvic-floor fascia, precisely reaching deep-seated lesions in the prostate and pelvic-floor nerves, ameliorating chronic pelvic-floor damage; through controlled micro-energy ultrasound stimulation, it enhances local pelvic-floor blood circulation, optimises the tissue microenvironment, and accelerates the repair of damaged nerves and soft tissue, thereby supporting the recovery of pelvic-floor function.
The entire procedure adopts an extracorporeal, non-invasive mode of diagnosis and treatment—no surgery, no catheterisation is required. Standardised treatment can be completed simply by applying a surface probe, substantially reducing the patient's procedural trauma and physical–psychological burden. The product has received China NMPA approval for tissue-repair indications and has been incorporated into CP/CPPS standardised treatment protocols by domestic and international expert consensuses, with its clinical value widely recognised by the industry.
Converging on Academic Innovation: Leading the New Future of Andrological Micro-Energy Medicine
The conference showcased the frontier achievements of China's urological-andrological domain across multiple perspectives, while further validating LIPUS non-invasive diagnosis and treatment as the prevailing developmental trajectory of the industry. Going forward, WBL Medical Group will remain committed to its innovation-driven founding mission, take LIPUS core technology as its anchor, and continue to deepen its academic collaboration and research co-development with leading authorities in urology and andrology across China.
WBL LIPUS Low-Intensity Pulsed Ultrasound
WBL LIPUS technology was initiated and advocated by Academician Guo Yinglu of the Chinese Academy of Engineering. Through years of transnational collaborative research and development with the team of Professors Fu-Kay (Frank) Liu and Tom Lue at the University of California, San Francisco (UCSF) in the United States, together with the team of Professor Xin Zhongcheng at Peking University First Hospital, the research group identified optimal parameter combinations—frequency, pulse intensity and emission mode—and established a foundational R&D system. After years of clinical translation and iterative refinement, WBL LIPUS has been formally applied in andrological clinical practice, breaking the long-standing monopoly of imported technologies in the domestic micro-energy andrology field and providing robust technical support for the standardised application of micro-energy medicine in China.
Technical Principle
The core mechanism of the WBL LIPUS Low-Intensity Pulsed-Ultrasound ED Therapeutic Platform is the application of low-energy pulsed ultrasound (acoustic intensity 50–350 mW/cm²) to penile cavernous tissue. The modality activates endogenous stem cells, promotes vascular and neural regeneration, and repairs damaged vascular endothelium and neural matrix, thereby pathologically improving erectile function. Built upon this technology, the platform delivers a non-invasive, painless and highly precise treatment, markedly enhancing the clinical efficacy and patient experience of ED management.
Three Core Advantages
1. Non-invasive, Safe and Painless
No surgery or injection is required. Treatment is delivered solely through an extracorporeal device, avoiding the risks and discomfort associated with conventional surgical procedures.
2. Promotes Tissue Repair and Regeneration
Ultrasound stimulates angiogenesis, improves local blood circulation and concurrently promotes the recovery of neural function.
3. Significant and Enduring Efficacy
Clinical studies have shown that, after multiple treatment sessions, patients' erectile function scores improve significantly, with the effects being both long-lasting and stable.
Guideline Consensus—Expert Recommendations
As LIPUS technology has gained broad consensus-based recognition within the industry, authoritative Chinese academic societies have, since 2020, successively issued guidelines and consensuses that unanimously endorse and recommend WBL LIPUS for the clinical treatment of ED:
Andrologist Branch of Chinese Medical Doctor Association, "Expert Consensus on the Diagnosis and Treatment of Erectile Dysfunction" (2020 Edition)
Asia Pacific Society of Sexual Medicine, "Clinical Practice Guideline Recommendations on Low-Intensity Extracorporeal Shockwave and Low-Intensity Pulsed Ultrasound in the Treatment of Erectile Dysfunction" (2021 Edition)
Chinese Medical Association—Society of Andrology, "Guidelines for the Diagnosis and Treatment of Erectile Dysfunction" (2022 Edition)
Urology Committee of Chinese Association of Integrative Medicine, "Expert Consensus on the Diagnosis and Treatment of Erectile Dysfunction with Integrative Chinese and Western Medicine" (2022 Edition)
Chinese Medical Association—Society of Andrology, "Guidelines for the Diagnosis and Treatment of Andrological Diseases" (2022 Edition)
Urology and Reproductive Health Branch of China International Exchange and Promotive Association for Medical and Health Care, "Chinese Expert Consensus on Low-Intensity Pulsed Ultrasound (LIPUS) in the Treatment of Erectile Dysfunction" (2024 Edition)
Energy Medicine and Andrological Equipment Branch of Chinese Sexology Association, "Chinese Expert Consensus on Low-Intensity Extracorporeal Shockwave/Pulsed Ultrasound in the Treatment of Erectile Dysfunction" (2024 Edition)
"Surgical Treatment of Erectile Dysfunction (2nd Edition, 2026)" co-edited by Academician Guo Yinglu, Professor Xin Zhongcheng and Professor Fu-Kay (Frank) Liu.
